Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04585490 |
|
Recruitment Status :
Recruiting
First Posted : October 14, 2020
Last Update Posted : April 17, 2024
|
Sponsor:
Maximilian Diehn
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Maximilian Diehn, Stanford University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 1, 2026 |
| Estimated Study Completion Date : | April 1, 2028 |